Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Entomol Products is a private U.S. company developing and commercializing plant-based insect repellent products built around hydrogenated catmint oil, an EPA-registered active ingredient derived from Nepeta cataria. The company markets on-skin repellents and private-label formulations, and it positions its business around a vertically integrated model spanning crop genetics, grower networks, ingredient production, formulation, bottling, and distribution. Entomol also appears to be expanding its technology beyond personal insect repellents into spatial repellent and antiviral fogging applications, including work related to avian influenza control. Its activities sit at the intersection of consumer health, vector-borne disease prevention, and agricultural biosecurity. The company is not a therapeutics biotech in the conventional drug-development sense, but it is health-related because its products are used to reduce exposure to disease-carrying insects and environmental pathogens.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Entomol Products.